Raw Ground Truth
Key Inclusion Criteria:Plasma HIV-1 RNA ≥ 500 copies/mL at screening VisitCurrently taking a failing ARV regimen that contains 2 NRTIs and a NNRTINo prior or current ARV regimens containing integrase inhibitor (INSTI) or protease inhibitor (PI)Screening genotype must show at least the protocol defined resistance mutation profileKey Exclusion Criteria:Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trialUse of an investigational drug other than the study drugIndividuals with chronic hepatitis B virus (HBV) infection are not permitted to participateActive tuberculosis infectionNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Raw Prediction
Key Inclusion Criteria:Plasma HIV-1 RNA ≥ 500 copies/mL at Screening VisitCurrently taking a failing antiretroviral (ARV) regimen that contains 2 NRTIs and a non-NRTI (NNRTI)No prior or current ARV regimens containing integrase inhibitor (INSTI) or protease inhibitor (PI)Screening genotype must show at least the protocol defined resistance mutation profileKey Exclusion Criteria:Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trialUse of an investigational drug other than the study drugIndividuals with chronic hepatitis B virus (HBV) infection are not permitted to participateActive tuberculosis infection
Processed Ground Truth
1. Key Inclusion Criteria:Plasma HIV-1 RNA ≥ 500 copies/mL at screening VisitCurrently taking a failing ARV regimen that contains 2 NRTIs and a NNRTINo prior or current ARV regimens containing integrase inhibitor (INSTI) or protease inhibitor (PI)Screening genotype must show at least the protocol defined resistance mutation profileKey Exclusion Criteria:Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trialUse of an investigational drug other than the study drugIndividuals with chronic hepatitis B virus (HBV) infection are not permitted to participateActive tuberculosis infectionNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Processed Prediction
1. Key Inclusion Criteria:Plasma HIV-1 RNA ≥ 500 copies/mL at Screening VisitCurrently taking a failing antiretroviral (ARV) regimen that contains 2 NRTIs and a non-NRTI (NNRTI)No prior or current ARV regimens containing integrase inhibitor (INSTI) or protease inhibitor (PI)Screening genotype must show at least the protocol defined resistance mutation profileKey Exclusion Criteria:Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trialUse of an investigational drug other than the study drugIndividuals with chronic hepatitis B virus (HBV) infection are not permitted to participateActive tuberculosis infection